LumiraDx Limited Stock price

Equities

LMDXF

KYG5709L1095

Advanced Medical Equipment & Technology

Delayed OTC Markets 02:50:01 2024-03-28 pm EDT 5-day change 1st Jan Change
0.0078 USD +2.63% Intraday chart for LumiraDx Limited -7.14% -87.60%
Sales 2021 421.43 Sales 2022 254.48 Capitalization 286M
Net income 2021 -101M Net income 2022 -448M EV / Sales 2021 5,817,897 x
Net Debt 2021 200M Net Debt 2022 347M EV / Sales 2022 2,487,758 x
P/E ratio 2021
-14.4 x
P/E ratio 2022
-0.57 x
Employees 1,210
Yield 2021 *
-
Yield 2022
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.63%
1 week-7.14%
Current month-11.36%
1 month-12.36%
3 months-87.87%
6 months-96.82%
Current year-87.60%
More quotes
1 week
0.01
Extreme 0.007
0.01
1 month
0.01
Extreme 0.007
0.01
Current year
0.01
Extreme 0.007
0.06
1 year
0.01
Extreme 0.007
0.87
3 years
0.01
Extreme 0.007
11.09
5 years
0.00
Extreme 0
11.09
10 years
0.00
Extreme 0
11.09
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 13-12-31
Founder 67 13-12-31
Director of Finance/CFO 49 16-10-31
Members of the board TitleAgeSince
Founder 67 13-12-31
Chief Executive Officer 70 13-12-31
Director/Board Member 69 16-10-31
More insiders
Date Price Change Volume
24-03-28 0.0078 +2.63% 615 425
24-03-27 0.0076 -11.63% 832,066
24-03-26 0.0086 +3.61% 374,705
24-03-25 0.0083 0.00% 1,133,575
24-03-22 0.0083 -1.19% 705,597

Delayed Quote OTC Markets, March 28, 2024 at 02:50 pm EDT

More quotes
LumiraDx Limited is a point of care diagnostic company. The Company is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The Company has developed and launched the LumiraDx Platform, which is an integrated system comprised of a small, versatile Instrument, low-cost microfluidic Test Strips, and seamless, secure digital connectivity. The Company offers a menu of lab comparable tests on a single portable platform, with more than 30 assays on the market and in various stages of development, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. It also supports laboratory testing in an accessible high-throughput format to leverage molecular laboratory operations. Its diagnostic testing solutions are being deployed globally by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools and others.
More about the company
  1. Stock
  2. Equities
  3. Stock LumiraDx Limited - OTC Markets